India’s Price Watchdog Mulls Price Caps On Selected Oncology Drugs
This article was originally published in PharmAsia News
Executive Summary
India’s NPPA has started a consultative process with stakeholders on including several key anticancer drugs in the new list of essential medicines in India. If the decision goes through, widely used products like trastuzumab, erlotinib and rituximab may be brought under price controls.